Dice Therapeutics Aces First Study -- but Put the Champagne on Ice
Investors for months were anxiously awaiting the first-ever clinical data from Dice Therapeutics (DICE). The results didn't disappoint them. The company's lead drug candidate, DC-806, aced a small phase 1 study focused on psoriasis.
Wednesday, October 12, 2022 at 2:04 pm